KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KNTE

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/03	22 : 00	GlobeNewswire Inc.	XOMA Corporation Announces Closing of Tender Offer	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/20	05 : 05	GlobeNewswire Inc.	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/06	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/06	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/05	07 : 27	Edgar (US Regulatory)	Form SC 14D9 - Solicitation, recommendation statements	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 53	Edgar (US Regulatory)	Form SC14D9C - Written communication relating to third party tender offer	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 35	PR Newswire (US)	Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 35	PR Newswire (US)	Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 35	PR Newswire (Canada)	Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/03/01	22 : 30	GlobeNewswire Inc.	Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/21	20 : 01	Edgar (US Regulatory)	Form SC14D9C - Written communication relating to third party tender offer	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/17	07 : 57	PR Newswire (US)	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/17	00 : 46	PR Newswire (US)	Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law Firm	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/16	23 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/16	22 : 00	GlobeNewswire Inc.	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/16	22 : 00	GlobeNewswire Inc.	Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/02/14	23 : 21	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:KNTE	Kinnate Biopharma Inc
2024/01/17	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/12/06	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/12/06	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/11/15	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/11/10	06 : 21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/11/10	06 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/11/10	06 : 05	GlobeNewswire Inc.	Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/09/19	05 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/09/19	05 : 10	GlobeNewswire Inc.	Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/09/07	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/09/07	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KNTE	Kinnate Biopharma Inc
2023/08/09	05 : 48	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KNTE	Kinnate Biopharma Inc